First-time generic approvals May 2010
Generic drugs approved by FDA (through April 2010): Losartan potassium tablets in 25-mg, 50-mg, and 100-mg, Losartan potassium and hydrochlorothiazide tablets in 50 mg/12.5 mg, 100 mg/12.5-mg, and 100 mg/25 mg, Hydromorphone hydrochloride injection, Mesna injection
Losartan potassium tablets in 25-mg, 50-mg, and 100-mg strengths (equiv to Cozaar)
TEVA PHARMACEUTICALS
Losartan potassium and hydrochlorothiazide tablets in 50 mg/12.5 mg, 100 mg/12.5-mg, and 100 mg/25 mg strengths (equiv to Hyzaar)
Hydromorphone hydrochloride injection 10 mg/mL in 1-, 5-, and 50-mL doses (equiv to Dilaudid-HP 10 mg/mL injection)
AKORN
Mesna injection in 1 mg per 10 mL multi-dose vials (equiv to Mesnex)
STRIDES ARCOLAB
David Calabrese of OptumRx Talks Top Three Drugs in Pipeline, Industry Trends in Q2
July 1st 2020In this week's episode of Tuning Into The C-Suite podcast, MHE's Briana Contreras chatted with David Calabrese, R.Ph, MHP, who is senior vice president and chief pharmacy officer of pharmacy care services company, OptumRx. David is also a member of Managed Healthcare Executives’ Editorial Advisory Board. During the discussion, he shared the OptumRx Quarter 2 Drug Pipeline Insights Report of 2020. Some of the information shared includes the three notable drugs currently being reviewed or those that have been recently approved by the FDA. Also discussed were any interesting industry trends to watch for.
Listen
